Clinical trial
A 28 Week, Treatment Randomized, Double -Blind, Placebo-controlled Study of the Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)
NCT01097694 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A 28 Week, Treatment Randomized, Double -Blind, Placebo-controlled Study of the Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)
- Lead sponsor
- Brigham and Women's Hospital
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 30, 2010
- Completion date
- August 31, 2016
- Enrollment
- 176 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.